Skip to main content

Table 2 Multivariate hazard ratios, confidence intervals, and p values

From: Multimodality treatment of brain metastases: an institutional survival analysis of 275 patients

 

Hazard Ratio

Estimate

95% CI

p value**

Treatment Groups

SRS*

reference

Surgery + SRS

0.68

0.49-0.94

0.020

WBRT + SRS

0.99

0.93-1.05

0.660

Surgery + WBRT + SRS

0.79

0.61-1.02

0.070

WBRT

1.94

1.37-2.73

<0.001

Surgery + WBRT

1.04

0.76-1.43

0.800

Age at diagnosis

<65*

reference

≥65

1.21

0.91-1.62

0.190

ECOG-PS

0*

reference

1

1.07

0.58-1.95

0.830

2

1.67

1.02-2.72

0.040

3

4.58

4.28-4.91

<0.001

4

11.26

5.98-21.2

<0.001

Primary Tumor Histology

NSCLC*

reference

SCLC

1.11

0.97-1.26

0.130

Breast

0.87

0.78-0.96

<0.001

Melanoma and Renal-cell

1.17

1.06-1.3

<0.001

Other

1.41

0.95-2.1

0.080

  1. ECOG-PS = Eastern Cooperative Oncology Group-Performance Status; NSCLC = non-small-cell lung cancer; SCLC = small-cell lung cancer; SRS = stereotactic radiosurgery; WBRT = whole brain radiation therapy
  2. * Reference group against which other groups' survival experience are compared
  3. ** p value for test if groups' survival experience is same as reference group